Landscape of Invasive Fusariosis in Pediatric Cancer Patients: Results of a Multicenter Observational Study From Latin America
Fabianne Carlesse,Adriana Maria Paixão de Sousa da Silva,Jaques Sztajnbok,Nadia Litivinov,Karina Peron,Marcelo Otsuka,Mariana Volpe Arnoni,Marcelo Schirmer,Patricia de Oliveira Costa,Ana Lucia Munhoz Cavalcanti de Albuquerque,Hugo Morales,Eduardo Lopez-Medina,Carlos A Portilla,Romina Valenzuela,Fabrizio Motta,Fabio Araújo Motta,João Nobrega de Almeida Junior,Maria Elena Santolaya,Arnaldo Lopes Colombo
DOI: https://doi.org/10.1093/ofid/ofae285
2024-05-17
Abstract:Invasive fusariosis (IF) is a life-threatening opportunistic infection that affects vulnerable hosts. We conducted a multicenter and multinational retrospective study to characterize the natural history and clinical management of IF in pediatric cancer patients. We selected patients <18 years old who were sequentially hospitalized in 10 Latin American medical centers with a diagnosis of IF between 2002 and 2021. Data were collected using an electronic case report form complemented by a dictionary of terms. We assessed mortality rates at 30, 60, and 90 days. We collected data from 60 episodes of IF (median age, 9.8 years) that were mostly documented in patients with hematologic cancer (70%). Other risk conditions found were lymphopenia (80%), neutropenia (76.7%), and corticosteroid exposure (63.3%). IF was disseminated in 55.6% of patients. Skin lesions was present in 58.3% of our patients, followed by pulmonary involvement in 55%, sinusitis in 21.7%, bone/joint involvement in 6.7% and 1 case each of endocarditis and brain abscess. Positive blood and skin biopsy cultures were detected in 60% and 48.3% of cases, respectively. Fusarium solani complex was the most commonly identified agent (66.6%). The majority of patients received monotherapy within the first 72 hours (71.6%), either with voriconazole or amphotericin B formulation. The mortality rates at 30, 60, and 90 days were 35%, 41.6%, and 45%, respectively. An important factor affecting mortality rates appears to be disseminated disease. The high percentage of patients with fungal involvement in multiple organs and systems highlights the need for extensive workup for additional sites of infection in severely immunocompromised children.